| |
Download our latest fact sheet to see how Catalent’s cell line development platform delivers unmatched efficiency, stability, and yield. Download Now.
|
|
Today’s Big NewsJun 20, 2025 |
|
In a capital-constrained environment, equipment financing offers a smart and flexible path forward. NFS Capital is here to help you keep innovating without waiting for your next funding round. Request more information.
|
|
| By Nick Paul Taylor The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its cell and gene therapy office on administrative leave and escorted her out of the agency. |
|
|
|
By Gabrielle Masson,Darren Incorvaia Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are reaching a whole new level. |
By James Waldron Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug. |
Sponsored by Thermo Fisher Scientific Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care. |
|
September 8-11, 2025 | Philadelphia, PA Join the industry's top minds at Fierce Pharma Week—where innovation, strategy, and partnerships converge. Don’t miss your chance to lead the future of pharma. Register Today.
|
|
By Nick Paul Taylor The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients. |
By James Waldron Life sciences investment firm Syncona has blamed “particularly challenging” market conditions for shifting its strategy away from early-stage biotechs and focusing on those companies likely to offer near-term rewards. |
By Gabrielle Masson Zealand Pharma is back with updated findings for its GLP-1/GLP-2 receptor dual agonist, finding mean body weight reductions rose to 11.6% for a higher dosing regimen after 28 weeks in a phase 1b trial. |
By Darren Incorvaia,Zoey Becker BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer. |
By Kevin Dunleavy Arialys has created a first-in-class precision medicine that is showing potential to become the first therapy to address the underlying cause of a rare brain disorder. |
By Fraiser Kansteiner In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from the panel’s planned meeting next week are confirming many industry watcher’s concerns about potential vaccine meddling by the Trump administration. |
By Angus Liu AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. Chinese regulators are proposing to shorten clinical trial review times for novel medicines. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
A pipeline-supporting marketing plan that includes proven tools, well-executed tactics, and a clear strategy are key to keeping your pipeline full of qualified leads. Access this valuable resource to discover how your marketing team can support your business development team in three essential areas: audience, storytelling, and performance. Download today!
|
|
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
